RE: H'mm19 Jun 2020 08:04
Further to the announcement on 29 May 2020, Catenae Innovation PLC (AIM: CTEA), the AIM quoted provider of digital media and technology, announces that its occupational health and wellness partner, Newcastle Premier Health Limited ("NPH") has completed the proof of concept pilot trial of the Company's Cov-ID app (the "Cov-ID Project").
NPH provided its clinical expertise to the Cov-ID Project and has been piloting the app since 29 May 2020.
The Cov-ID app is a COVID-19 status verification passport, designed to support the efforts of businesses and organisations in getting back to work, whilst safeguarding employees from the spread of COVID-19 by allowing the user ("Certificate Holder") to share and prove their COVID-19 status in a secure, immutable and GDPR compliant manner.
The objective of the pilot trial was to undertake a "proof of concept" of the app to determine that user management, certification management and user validation achieved their functionality targets which included, inter alia - importing, creating and archiving certificate and user data and viewing data via secure means through both one-way and two-way validation processes.
Both the one-way and two-way validation processes work across Android and iOS platforms.
The app allows a Certificate Holder to expose their COVID-19 anti-body testing status to a third-party "gate-keeper" via a single use QR code displayed on their device.
In one-way validation, the QR code is readable by any device equipped with QR scanner functionality or app. In two-way validation mode both the gate-keeper and the Certificate Holder use the app allowing the identity of the gate-keeper to be validated and restricting the display of the Certificate Holder's status solely to the gate-keeper. Additionally the event is logged and recorded to a blockchain repository.
The Cov-ID project is a joint initiative by a consortium of companies led by the Z/Yen Group.
Although the proof of concept stage of the app has been positive, there is no guarantee that it will be commercialised, nor that in the event that it is commercialised, that material revenues will be generated by the Company.